pargyline has been researched along with Kidney Failure, Chronic in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nestor, G | 1 |
| Beroniade, V | 1 |
| Tutunaru, M | 1 |
| Vidt, DG | 1 |
2 other studies available for pargyline and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Secondary effects of hypotensive drugs in arterial hypertension of renal origin].
Topics: Adult; Antihypertensive Agents; Female; Guanethidine; Humans; Hydralazine; Hypertension, Renal; Kidn | 1970 |
An approach to the medical treatment of hypertension in the aged.
Topics: Age Factors; Aged; Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Diuretics; | 1969 |